On another bustling day at the WTA 1000 Qatar TotalEnergies Open, Paula Badosa, Ons ... of 16. Jabeur's next match will be against No. 7 seed Zheng Qinwen of China, their first meeting since the 2023 ...

Jabeur is a former runner-up in Rome, going down to Swiatek in the 2022 final. The two have split their previous four meetings evenly to tie the head-to-head at 2-2. Jabeur won their first couple ...

On Monday, Guadalajara champion Jessica Pegula will reprise that tournament's final against Maria Sakkari before two-time major finalist Ons Jabeur faces Aryna Sabalenka. Here's how those matches ...

The WTA party in Rome comes alive on the fifth day with former champion Elina Svitolina and 2022 runner-up Ons Jabeur in ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

Zepbound Beats Wegovy for Weight Loss in First Head-To-Head Trial of Blockbuster Drugs People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Study MONDAY, May 12, 2025 (HealthDay News) — A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% ...

(AP Photo/JoNel Aleccia) People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the ...